Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Aug
21
Today In Oncology
Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced, Refractory Malignancies
Mosunetuzumab With Response-Adapted Therapy in Previously Untreated NHL
Study Supports Personalized Weight-Loss Intervention for Breast Cancer Survivors
Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment
County-Level Medical Debt Linked to Advanced-Stage Cancers, Worse Survival Among Newly Diagnosed U.S. Adults
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo